[{"id":"1a82176c-12db-4705-bb02-3bf4a332887d","acronym":"DELTA-2","url":"https://clinicaltrials.gov/study/NCT05393635","created_at":"2022-05-26T16:55:29.932Z","updated_at":"2024-07-02T16:35:58.890Z","phase":"Phase 1","brief_title":"ITIL-168 in Advanced Solid Tumors","source_id_and_acronym":"NCT05393635 - DELTA-2","lead_sponsor":"Instil Bio","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • ITIL-168"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 12/08/2022","primary_completion_date":" 12/08/2022","study_txt":" Completion: 12/08/2022","study_completion_date":" 12/08/2022","last_update_posted":"2022-12-20"},{"id":"a80c3fb6-c7bd-415e-9426-6ddc23e06623","acronym":"","url":"https://clinicaltrials.gov/study/NCT04115761","created_at":"2021-01-18T20:07:07.765Z","updated_at":"2024-07-02T16:36:14.860Z","phase":"Phase 2","brief_title":"Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients","source_id_and_acronym":"NCT04115761","lead_sponsor":"Ever Supreme Bio Technology Co., Ltd.","biomarkers":" PD-L1 • IDH1 • CD8 • PD-1","pipe":" | ","alterations":" IDH wild-type • PD-1-L","tags":["PD-L1 • IDH1 • CD8 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type • PD-1-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ADCV01"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/06/2019","start_date":" 06/06/2019","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/30/2023","study_completion_date":" 12/30/2023","last_update_posted":"2022-03-23"}]